Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women

References

• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [Fracture Intervention Trial Research Group]. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J Am Med Assoc 1999;282:637–45
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial [Vertebral efficacy with risedronate therapy (VERT) study group]. J Am Med Assoc 1999;282:1344–52
   PubMed Web of Science ®Google Scholar
• Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987;156:1332–4
   PubMed Web of Science ®Google Scholar
• Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporosis Int 2003;14:965–8
   PubMed Web of Science ®Google Scholar
• Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004;26:245–56
   PubMed Web of Science ®Google Scholar
• Ryan PJ, Harrison R, Blake GM, et al. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol 1992;99:325–8
   PubMedGoogle Scholar
• Torgerson DJ, Donaldson C, Russell IT, et al. Hormone replacement therapy: compliance and cost after screening for osteoporosis. Eur J Obstet Gynaecol Reprod Biol 1995; 59:57–60
   PubMed Web of Science ®Google Scholar
• Ettinger B, Pressman A, Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause 1999;6:282–9
   Google Scholar
• Den Tonkelaar I, Oddens BJ. Determinants of long-term hormone replacement therapy and reasons for early discontinuation. Obstet Gynecol 2000;95:507–12
   PubMed Web of Science ®Google Scholar
• Ettinger B, Tosteson AN, Grove M, et al. Side effect severity and discontinuation rate among women initiating hormone replacement therapy, raloxifene, or alendronate following BMD testing. Bone 2001;28:S76
   Google Scholar
• Kayser J, Ettinger B, Pressman A. Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen. Menopause 2001;8:328–32
   Google Scholar
• Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115: 209–16
   PubMed Web of Science ®Google Scholar
• Clowes JA, Peel NFA, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117–23
   Google Scholar
• Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005;165:2414–9
   PubMed Web of Science ®Google Scholar
• Greendale GA, Wells B, Marcus R, et al. How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/ Progestin Interventions Trial. Arch Intern Med 2000;160: 3065–71
   PubMed Web of Science ®Google Scholar
• McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271–87
   Google Scholar
• Papaioannou A, Ioannidis G, Adachi JD, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporosis Int 2003;14:808–13
   PubMed Web of Science ®Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60
   PubMed Web of Science ®Google Scholar
• Brooks RG. EuroQoL – the current state of play. Health Policy 1996;37:53–72
   PubMed Web of Science ®Google Scholar
• Haynes RB, Sackett DL, Gibson ES, et al. Improvement of medication compliance in uncontrolled hypertension. Lancet 1976;1:1265–8
   PubMed Web of Science ®Google Scholar
• Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67–74
   Google Scholar
• Dolan P. Modeling valuations for EuroQoL health states. Medical Care 1997;35:1095–1108
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 2004;15:1003–8
   PubMed Web of Science ®Google Scholar
• Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006;119:S18–S24
   PubMed Web of Science ®Google Scholar
• Weiss M, Vered I, Foldes AJ, et al. Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res 2005;17:143–9
   PubMed Web of Science ®Google Scholar
• Kendler D, Kung AW, Fuleihan Gel-H, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004;48:243–51
   Google Scholar
• Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80: 856–61
   Google Scholar
• Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis Int 2006;17:1645–52
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006;28:236–42
   Google Scholar
• Rossini M, Bianchi G, Di Munno O, et al.; Treatment of Osteoporosis in clinical Practice (TOP) study group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporosis Int 2006;17:914–21
   Google Scholar
• Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002;24:1871–86
   PubMed Web of Science ®Google Scholar
• Mersfelder T, Armitstead JA, Ivey MF, Cedars M. A medication use evaluation of alendronate: compliance with administration guidelines. Pharm Pract Manag Q 1999;18:50–8
   PubMedGoogle Scholar
• Gold DT, McClung B. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med 2006;119:S32–S37
   PubMedGoogle Scholar